# EDGAR Filing Document

**Accession Number:** 0001099800
**File Stem:** 0001193125-25-164527
**Filing Date:** 2025-7
**Character Count:** 5176
**Document Hash:** 098fe4327647095a88a4948b6c6647ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-164527.hdr.sgml**: 20250725

**ACCESSION NUMBER**: 0001193125-25-164527

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250721

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20250725

**DATE AS OF CHANGE**: 20250724

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Edwards Lifesciences Corp
- **CENTRAL INDEX KEY:** 0001099800
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364316614
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15525
- **FILM NUMBER:** 251148111

**BUSINESS ADDRESS:**
- **STREET 1:** ONE EDWARDS WAY
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614
- **BUSINESS PHONE:** 9492502500

**MAIL ADDRESS:**
- **STREET 1:** ONE EDWARDS WAY
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EDWARDS LIFESCIENCES CORP.
- **DATE OF NAME CHANGE:** 20090225

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EDWARDS LIFESCIENCES CORP
- **DATE OF NAME CHANGE:** 20000203

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CVG CONTROLLED INC
- **DATE OF NAME CHANGE:** 19991126

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported) July 21, 2025

## EDWARDS LIFESCIENCES CORPORATION

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-15525** | **36-4316614** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>file number)** | **(IRS Employer<br>Identification No.)** |

---

#### One Edwards Way

#### Irvine, California 92614

#### (Address of principal executive offices and zip code)
(949) 250-2500

#### (Registrant's telephone number, including area code)

#### N/A

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $1.00 per share | EW | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**  |

---

*Departure of Named Executive Officer* 

On July 21, 2025, Larry L. Wood notified the Board of Directors of Edwards Lifesciences Corporation (the "Company") that he will resign from his position as Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart of the Company, effective September 1, 2025, to accept a senior leadership position at another company outside cardiovascular. In connection with Mr. Wood's departure, effective September 1, 2025, Daniel J. Lippis, the Company's current Corporate Vice President, Japan, Greater China and Asia Pacific, will serve as the Company's Corporate Vice President responsible for Transcatheter Aortic Valve Replacement.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **EDWARDS LIFESCIENCES CORPORATION** | **EDWARDS LIFESCIENCES CORPORATION** |
|  | By: | /s/ Mark D. Peterson |
|  |  | Mark D. Peterson |
| Date: July 25, 2025 |  | Corporate Vice President and General Counsel |

---